# Evidence for Health Improvement in People With Diabetes Using One Touch & Partner Solutions

Study · id `cardio:ct-nct05354297` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05354297](<https://clinicaltrials.gov/study/NCT05354297>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05354297

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 800 participants.

## Technical summary

Registry record NCT05354297. Non-randomized; no masking; primary purpose treatment. Start 2022-07-26 (anticipated); primary completion 2023-04-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 800 participants (planned count; ClinicalTrials.gov record NCT05354297, source copy `cardio:ctgov-nct05354297-2022-07-20`, retrieved 2026-10-26)
- Planned start: 2022-07-26 (anticipated) (ClinicalTrials.gov record NCT05354297, source copy `cardio:ctgov-nct05354297-2022-07-20`, retrieved 2026-10-26)
- Primary completion: 2023-04-01 (anticipated) (ClinicalTrials.gov record NCT05354297, source copy `cardio:ctgov-nct05354297-2022-07-20`, retrieved 2026-10-26)
- Completion: 2023-09-01 (anticipated) (ClinicalTrials.gov record NCT05354297, source copy `cardio:ctgov-nct05354297-2022-07-20`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT05354297, source copy `cardio:ctgov-nct05354297-2022-07-20`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05354297-2022-07-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: Evidence for Health Improvement in People With Diabetes Using One Touch & Partner Solutions
- Acronym: ECLIPSE
- Condition: Diabetes Mellitus, Type 2
- Intervention (Device): Cecelia Health plus OneTouch Verio Reflect® BGM and OneTouch Reveal® mobile app
- Intervention (Device): Fitbit plus OneTouch Verio Reflect® BGM and OneTouch Reveal® mobile app
- Intervention (Device): Noom plus OneTouch Verio Reflect® BGM and OneTouch Reveal® mobile app
- Intervention (Device): Welldoc plus OneTouch Verio Reflect® BGM and Welldoc app
- Lead sponsor: LifeScan
- Lead sponsor class: INDUSTRY
- Collaborator: Evidation Health
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: c465a81c7da191c77bf6a049be4f880d4457458905694044bc8fe14fb43a7c51
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
